<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>UNIVASC- moexipril hydrochloride tablet, film coated </strong><br>UCB, Inc.<br></p></div>
<h1>univasc<span class="Sup">® </span> tablets<br> (moexipril hydrochloride)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>FETAL TOXICITY</h2>
<p class="First"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></p>
<ul class="Disc">
<li>
<span class="Bold">When pregnancy is detected, discontinue univasc</span><span class="Sup">®</span><span class="Bold"> as soon as possible</span>.</li>
<li><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.  See <a href="#fetal">WARNINGS: Fetal Toxicity</a></span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">univasc<span class="Sup">®</span> (moexipril hydrochloride), the hydrochloride salt of moexipril, has the empirical formula C<span class="Sub">27</span>H<span class="Sub">34</span>N<span class="Sub">2</span>O<span class="Sub">7</span>•HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride. It is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5&amp;name=univasc-01.jpg"></div>
<p>Moexipril hydrochloride is a fine white to off-white powder. It is soluble (about 10% weight-to-volume) in distilled water at room temperature.</p>
<p>univasc<span class="Sup">®</span> is supplied as scored, coated tablets containing 7.5 mg and 15 mg of moexipril hydrochloride for oral administration. In addition to the active ingredient, moexipril hydrochloride, the tablet core contains the following inactive ingredients:  lactose, magnesium oxide, crospovidone, magnesium stearate and gelatin. The film coating contains hydroxypropyl cellulose, hypromellose, polyethylene glycol 6000, magnesium stearate, titanium dioxide, and ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Moexipril hydrochloride is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, increased plasma renin activity, and decreased aldosterone secretion. The latter results in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone, see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
<p>Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. As is the case with other ACE inhibitors, however, the antihypertensive effect of moexipril is considerably smaller in black patients, a predominantly low-renin population, than in non-black hypertensive patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2.1"></a><p></p>
<h3>Pharmacokinetics</h3>
<p class="First">Moexipril's antihypertensive activity is almost entirely due to its deesterified metabolite, moexiprilat. Bioavailability of oral moexipril is about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces the peak plasma level (C<span class="Sub">max</span>) and AUC (see <a href="#Absorption">Absorption</a>). Moexipril should therefore be taken in a fasting state. The time of peak plasma concentration (T<span class="Sub">max</span>) of moexiprilat is about 1½ hours and elimination half-life (t<span class="Sub">½</span>) is estimated at 2 to 9 hours in various studies, the variability reflecting a complex elimination pattern that is not simply exponential. Like all ACE inhibitors, moexiprilat has a prolonged terminal elimination phase, presumably reflecting slow release of drug bound to the ACE. Accumulation of moexiprilat with repeated dosing is minimal, about 30%, compatible with a functional elimination t<span class="Sub">½ </span>of about 12 hours. Over the dose range of 7.5 to 30 mg, pharmacokinetics are approximately dose proportional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Absorption"></a><a name="section-3.2.2"></a><p></p>
<h3>Absorption</h3>
<p class="First">Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13%. Bioavailability varies with formulation and food intake which reduces C<span class="Sub">max</span> and AUC by about 70% and 40% respectively after the ingestion of a low-fat breakfast or by 80% and 50% respectively after the ingestion of a high-fat breakfast. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">The clearance (CL) for moexipril is 441 mL/min and for moexiprilat 232 mL/min with a t<span class="Sub">½</span> of 1.3 and 9.8 hours, respectively. Moexiprilat is about 50% protein bound. The volume of distribution of moexiprilat is about 183 liters. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.4"></a><p></p>
<h3>Metabolism and Excretion</h3>
<p class="First">Moexipril is relatively rapidly converted to its active metabolite moexiprilat, but persists longer than some other ACE inhibitor prodrugs, such that its t<span class="Sub">½</span> is over one hour and it has a significant AUC. Both moexipril and moexiprilat are converted to diketopiperazine derivatives and unidentified metabolites. After I.V. administration of moexipril, about 40% of the dose appears in urine as moexiprilat, about 26% as moexipril, with small amounts of the metabolites; about 20% of the I.V. dose appears in feces, principally as moexiprilat. After oral administration, only about 7% of the dose appears in urine as moexiprilat, about 1% as moexipril, with about 5% as other metabolites. Fifty-two percent of the dose is recovered in feces as moexiprilat and 1% as moexipril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5.1"></a><p></p>
<h4><span class="Italics">Decreased Renal Function</span></h4>
<p class="First">The effective elimination t<span class="Sub">½</span> and AUC of both moexipril and moexiprilat are increased with decreasing renal function. There is insufficient information available to characterize this relationship fully, but at creatinine clearances in the range of 10 to 40 mL/min, the t<span class="Sub">½</span> of moexiprilat is increased by a factor of 3 to 4.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5.2"></a><p></p>
<h4><span class="Italics">Decreased Hepatic Function</span></h4>
<p class="First">In patients with mild to moderate cirrhosis given single 15 mg doses of moexipril, the C<span class="Sub">max</span> of moexipril was increased by about 50% and the AUC increased by about 120%, while the C<span class="Sub">max</span> for moexiprilat was decreased by about 50% and the AUC increased by almost 300%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5.3"></a><p></p>
<h4><span class="Italics">Elderly Patients</span></h4>
<p class="First">In elderly male subjects (65-80 years old) with clinically normal renal and hepatic function, the AUC and C<span class="Sub">max</span> of moexiprilat is about 30% greater than those of younger subjects (19-42 years old).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic Interactions</span> With Other Drugs</h3>
<p class="First">No clinically important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> occurred when univasc<span class="Sup">®</span> was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Pharmacodynamics and Clinical Effect</h2>
<p class="First">Single and multiple doses of 15 mg or more of univasc<span class="Sup">®</span> gives sustained inhibition of plasma ACE activity of 80-90%, beginning within 2 hours and lasting 24 hours (80%).</p>
<p>In controlled trials, the peak effects of orally administered moexipril increased with the dose administered over a dose range of 7.5 to 60 mg, given once a day. Antihypertensive effects were first detectable about 1 hour after dosing, with a peak effect between 3 and 6 hours after dosing. Just before dosing (i.e., at trough), the antihypertensive effects were less prominently related to dose and the antihypertensive effect tended to diminish during the 24-hour dosing interval when the drug was administered once a day.</p>
<p>In multiple dose studies in the dose range of 7.5 to 30 mg once daily, univasc<span class="Sup">®</span> lowered sitting diastolic and systolic blood pressure effects at trough by 3 to 6 mmHg and 4 to 11 mmHg more than placebo, respectively. There was a tendency toward increased response with higher doses over this range. These effects are typical of ACE inhibitors but, to date, there are no trials of adequate size comparing moexipril with other antihypertensive agents.</p>
<p>The trough diastolic blood pressure effects of moexipril were approximately 3 to 6 mmHg in various studies. Generally, higher doses of moexipril leave a greater fraction of the peak blood pressure effect still present at trough. During dose titration, any decision as to the adequacy of a dosing regimen should be based on trough blood pressure measurements. If diastolic blood pressure control is not adequate at the end of the dosing interval, the dose can be increased or given as a divided (BID) regimen.</p>
<p>During chronic therapy, the antihypertensive effect of any dose of univasc<span class="Sup">®</span> is generally evident within 2 weeks of treatment, with maximal reduction after 4 weeks. The antihypertensive effects of univasc<span class="Sup">®</span> have been proven to continue during therapy for up to 24 months.</p>
<p>univasc<span class="Sup">®</span>, like other ACE inhibitors, is less effective in decreasing trough blood pressures in blacks than in non-blacks. Placebo-corrected trough group mean diastolic blood pressure effects in blacks in the proposed dose range varied between +1 to -3 mmHg compared with responses in non-blacks of -4 to -6 mmHg.</p>
<p>The effectiveness of univasc<span class="Sup">®</span> was not significantly influenced by patient age, gender, or weight. univasc<span class="Sup">®</span> has been shown to have antihypertensive activity in both pre- and postmenopausal women who have participated in placebo-controlled clinical trials.</p>
<p>Formal interaction studies with moexipril have not been carried out with antihypertensive agents other than thiazide diuretics. In these studies, the added effect of moexipril was similar to its effect as monotherapy. In general, ACE inhibitors have less than additive effects with beta-adrenergic blockers, presumably because both work by inhibiting the renin-angiotensin system.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">univasc<span class="Sup">®</span> is indicated for treatment of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with thiazide diuretics.</p>
<p>In using univasc<span class="Sup">®</span>, consideration should be given to the fact that another ACE inhibitor, captopril, has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or collagen-vascular disease. Available data are insufficient to show that univasc<span class="Sup">®</span> does not have a similar risk (see <a href="#WARNINGS">WARNINGS</a>).</p>
<p>In considering use of univasc<span class="Sup">®</span>, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in black than in non-black patients (see <a href="#WARNINGS">WARNINGS</a>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">univasc<span class="Sup">®</span> is contraindicated in patients who are hypersensitive to this product and in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> related to previous treatment with an ACE inhibitor.</p>
<p>Do not co-administer aliskiren with univasc<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <a href="#PreDI">PRECATIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Anaphylactoid and Possibly Related Reactions</h2>
<p class="First">Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors, including univasc<span class="Sup">®</span>, may be subject to a variety of adverse reactions, some of them serious.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> involving the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with ACE inhibitors, including univasc<span class="Sup">®</span>. Symptoms suggestive of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> occurred in &lt;0.5% of moexipril-treated patients in placebo-controlled trials. None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). One patient treated with hydrochlorothiazide alone experienced <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>. No instances of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> were reported in placebo-treated patients. </p>
<p>In cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, treatment should be promptly discontinued and the patient carefully observed until the <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> disappears. In instances where <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with involvement of the tongue, glottis, or larynx, may be fatal due to airway obstruction. Appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) and/or measures to ensure a patent airway, should be promptly provided</span> (see <a href="#AR">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Desensitization</h3>
<p class="First">Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions did not occur when ACE inhibitors were temporarily withheld, but they reappeared when the ACE inhibitors were inadvertently readministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">univasc<span class="Sup">®</span> can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, although, as with other ACE inhibitors, this is unusual in uncomplicated hypertensive patients treated with univasc<span class="Sup">®</span> alone. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was seen in 0.5% of patients given moexipril and led to discontinuation of therapy in about 0.25%. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is most likely to occur in patients who have been salt- and volume-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Volume- and salt-depletion should be corrected and, in general, diuretics stopped, before initiating therapy with univasc<span class="Sup">®</span> (see <a href="#PreDI">PRECAUTIONS, Drug Interactions</a>, and <a href="#AR">ADVERSE REACTIONS</a>).</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, with or without associated <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, ACE inhibitor therapy may cause excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely, with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In these patients, univasc<span class="Sup">®</span> therapy should be started under close medical supervision, and patients should be followed closely for the first two weeks of treatment and whenever the dose of moexipril or an accompanying diuretic is increased. Care in avoiding <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should also be taken in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>, or cerebrovascular disease, in whom an excessive decrease in blood pressure could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in a supine position and, if necessary, treated with an intravenous infusion of normal saline. univasc<span class="Sup">®</span> treatment usually can be continued following restoration of blood pressure and volume.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">Another ACE inhibitor, captopril, has been shown to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, rarely in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span>, but more frequently in hypertensive patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, especially if they also have a collagen-vascular disease such as <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> or <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>. Although there were no instances of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;500/mm<span class="Sup">3</span>) among patients given univasc<span class="Sup">®</span>, as with other ACE inhibitors, monitoring of white blood cell counts should be considered for patients who have collagen-vascular disease, especially if the disease is associated with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Available data from clinical trials of univasc<span class="Sup">®</span> are insufficient to show that univasc<span class="Sup">®</span> does not cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> at rates similar to captopril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="fetal"></a><a name="section-6.4"></a><p></p>
<h2>Fetal Toxicity</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations.  Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  When pregnancy is detected, discontinue univasc<span class="Sup">®</span> as soon as possible.  These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy.  Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.  Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus. </p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.  Perform serial ultrasound examinations to assess the intra-amniotic environment.  If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue univasc<span class="Sup">®</span>, unless it is considered lifesaving for the mother.  Fetal testing may be appropriate, based on the week of pregnancy.  Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.  Closely observe infants with histories of <span class="Italics">in utero</span> exposure to univasc<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. (see <a href="#pediatric">Precautions, Pediatric Use</a>).</p>
<p>No embryotoxic, fetotoxic, or teratogenic effects were seen in rats or in rabbits treated with up to 90.9 and 0.7 times, respectively, the Maximum Recommended Human Dose (MRHD) on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></h2>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="PreGen"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></p>
<p>As a consequence of inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. There is no clinical experience of univasc<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. </p>
<p>Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when univasc<span class="Sup">®</span> has been given concomitantly with a thiazide diuretic. This is more likely to occur in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There may be a need for dose adjustment of univasc<span class="Sup">®</span> and/or the discontinuation of the thiazide diuretic. </p>
<p><span class="Bold">Evaluation of hypertensive patients should always include assessment of renal function</span> (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Italics">Hypertensive Patients With <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></p>
<p>In hypertensive patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including univasc<span class="Sup">®</span>, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and, rarely, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<p class="First"><span class="Italics">Hypertensive Patients With <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">Renal Artery Stenosis</span></span></p>
<p>In hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine have been observed in some patients following ACE inhibitor therapy. These increases were almost always reversible upon discontinuation of the ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></p>
<p>In clinical trials, persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium above 5.4 mEq/L) occurred in approximately 1.3% of hypertensive patients receiving univasc<span class="Sup">®</span>. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with ACE inhibitors include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with univasc<span class="Sup">®</span> (see <a href="#PreDI">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.5"></a><p></p>
<p class="First"><span class="Italics">Surgery/Anesthesia</span></p>
<p>In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, moexipril may block the effects of compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs in this setting and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></p>
<p>Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. In controlled trials with moexipril, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> was present in 6.1% of moexipril patients and 2.2% of patients given placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Italics">Food</span></p>
<p>Patients should be advised to take moexipril one hour before meals (see <a href="#CP">CLINICAL PHARMACOLOGY</a> and <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, may occur with treatment with ACE inhibitors, usually occurring early in therapy (within the first month). Patients should be so advised and told to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more univasc<span class="Sup">®</span> until they have consulted with the prescribing physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></p>
<p>Patients should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur with univasc<span class="Sup">®</span>, especially during the first few days of therapy. If <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> occurs, the patient should stop taking univasc<span class="Sup">®</span> and consult the prescribing physician.</p>
<p>All patients should be cautioned that excessive perspiration and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume. Other causes of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> such as <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may also lead to a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>; patients should be advised to consult their physician if they develop these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></p>
<p>Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p>Patients should be told to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) that could be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.6"></a><p></p>
<p class="First"><span class="Italics">Pregnancy</span></p>
<p>Female patients of childbearing age should be told about the consequences of  exposure to univasc<span class="Sup">®</span> during pregnancy.  Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreDI"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<p class="First"><span class="Italics">Diuretics</span></p>
<p>Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with univasc<span class="Sup">®</span> can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc<span class="Sup">®</span>. If this is not possible, the starting dose of moexipril should be reduced. (See <a href="#WARNINGS">WARNINGS</a> and <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<p class="First"><span class="Italics">Potassium Supplements and Potassium-Sparing Diuretics</span></p>
<p>univasc<span class="Sup">® </span>can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patient's serum potassium should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<p class="First"><span class="Italics">Oral Anticoagulants</span></p>
<p>Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<p class="First"><span class="Italics">Lithium</span></p>
<p>Increased serum lithium levels and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving ACE inhibitors during therapy with lithium. These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> may be increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5"></a><p></p>
<p class="First"><span class="Italics">Gold</span></p>
<p>Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including univasc<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6"></a><p></p>
<p class="First"><span class="Italics">Non-steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span></p>
<p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDS, including selective COX-2 inhibitors, with ACE inhibitors, including moexipril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  These effects are usually reversible.  Monitor renal function periodically in patients receiving moexipril and NSAID therapy.</p>
<p>The antihypertensive effect of ACE inhibitors, including moexipril, may be attenuated by NSAIDS. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.7"></a><p></p>
<p class="First"><span class="Italics">Dual Blockade of the Renin-Angiotensin System (RAS)</span></p>
<p>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on univasc<span class="Sup">®</span> and other agents that affect the RAS.</p>
<p>Do not co-administer aliskiren with univasc<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with univasc<span class="Sup">®</span> in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 mL/min).    </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.8"></a><p></p>
<p class="First"><span class="Italics">Other Agents</span></p>
<p>No clinically important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> occurred when univasc<span class="Sup">®</span> was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.</p>
<p>univasc<span class="Sup">®</span> has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H<span class="Sub">2</span> blockers, digoxin, oral hypoglycemic agents, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering agents. There was no evidence of clinically important adverse interactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No evidence of carcinogenicity was detected in long-term studies in mice and rats at doses up to 14 or 27.3 times the Maximum Recommended Human Dose (MRHD) on a mg/m<span class="Sup">2</span> basis.</p>
<p>No mutagenicity was detected in the Ames test and microbial reverse mutation assay, with and without metabolic activation, or in an <span class="Italics">in vivo</span> nucleus anomaly test. However, increased chromosomal aberration frequency in Chinese hamster ovary cells was detected under metabolic activation conditions at a 20-hour harvest time.</p>
<p>Reproduction studies have been performed in rabbits at oral doses up to 0.7 times the MRHD on a mg/m<span class="Sup">2</span> basis, and in rats up to 90.9 times the MRHD on a mg/m<span class="Sup">2 </span>basis. No indication of impaired fertility, reproductive toxicity, or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether univasc<span class="Sup">®</span> is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when univasc<span class="Sup">®</span> is given to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1"></a><p></p>
<h3><span class="Underline">Neonates with a history of <span class="Italics">in utero</span> exposure to univasc<span class="Sup">®</span></span></h3>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion.  Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.2"></a><p></p>
<p class="First">Safety and effectiveness of univasc<span class="Sup">®</span> in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of univasc<span class="Sup">®</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">univasc<span class="Sup">®</span> has been evaluated for safety in more than 2500 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; more than 250 of these patients were treated for approximately one year. The overall incidence of reported adverse events was only slightly greater in patients treated with univasc<span class="Sup">®</span> than patients treated with placebo.</p>
<p>Reported adverse experiences were usually mild and transient, and there were no differences in adverse reaction rates related to gender, race, age, duration of therapy, or total daily dosage within the range of 3.75 mg to 60 mg. Discontinuation of therapy because of adverse experiences was required in 3.4% of patients treated with univasc<span class="Sup">®</span> and in 1.8% of patients treated with placebo. The most common reasons for discontinuation in patients treated with univasc<span class="Sup">®</span> were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (0.7%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.4%).</p>
<p>All adverse experiences considered at least possibly related to treatment that occurred at any dose in placebo-controlled trials of once-daily dosing in more than 1% of patients treated with univasc<span class="Sup">®</span> alone and that were at least as frequent in the univasc<span class="Sup">®</span> group as in the placebo group are shown in the following table:</p>
<table width="75%">
<caption><span>ADVERSE EVENTS IN PLACEBO-CONTROLLED STUDIES</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="center">ADVERSE EVENT</th>
<th class="Lrule" align="center">UNIVASC<br>(N=674)</th>
<th class="Lrule Rrule" align="center">PLACEBO<br>(N=226)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">N (%)</th>
<th class="Lrule Rrule" align="center">N (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></td>
<td class="Lrule" align="center">41 (6.1)</td>
<td class="Lrule Rrule" align="center">5 (2.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">29 (4.3)</td>
<td class="Lrule Rrule" align="center">5 (2.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">21 (3.1)</td>
<td class="Lrule Rrule" align="center">5 (2.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span></td>
<td class="Lrule" align="center">21 (3.1)</td>
<td class="Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">16 (2.4)</td>
<td class="Lrule Rrule" align="center">4 (1.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Lrule" align="center">12 (1.8)</td>
<td class="Lrule Rrule" align="center">2 (0.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Lrule" align="center">11 (1.6)</td>
<td class="Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">11 (1.6)</td>
<td class="Lrule Rrule" align="center">2 (0.9)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule" align="center">9 (1.3)</td>
<td class="Lrule Rrule" align="center">0 (0)</td>
</tr>
</tbody>
</table>
<p>Other adverse events occurring in more than 1% of patients on moexipril that were at least as frequent on placebo include:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>. See <a href="#WARNINGS">WARNINGS</a> and <a href="#PRECAUTIONS">PRECAUTIONS </a> for discussion of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, second and third trimester fetal/neonatal morbidity and mortality, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
<p>Other potentially important adverse experiences reported in controlled or uncontrolled clinical trials in less than 1% of moexipril patients or that have been attributed to other ACE inhibitors include the following:</p>
<p><span class="Bold Italics">Cardiovascular:</span> Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were seen in 9/1750 (0.51%) patients; these reactions led to discontinuation of therapy in controlled trials in 3/1254 (0.24%) patients who had received univasc<span class="Sup">®</span> monotherapy and in 1/344 (0.3%) patients who had received univasc<span class="Sup">®</span> with hydrochlorothiazide (see <a href="#PRECAUTIONS">PRECAUTIONS </a> and <a href="#WARNINGS">WARNINGS</a>). Other adverse events included angina/<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, rhythm disturbances, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p><span class="Bold Italics">Renal:</span> Of hypertensive patients with no apparent preexisting <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, 1% of patients receiving univasc<span class="Sup">®</span> alone and 2% of patients receiving univasc<span class="Sup">®</span> with hydrochlorothiazide experienced increases in serum creatinine to at least 140% of their baseline values (see <a href="#PRECAUTIONS">PRECAUTIONS </a>and <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, appetite/weight change, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Bold Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>.</p>
<p><span class="Bold Italics">Dermatologic:</span> Apparent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> manifested by <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
<p><span class="Bold Italics">Neurological and Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p><span class="Bold Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (see <a href="#WARNINGS">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbances</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Clinical Laboratory Test Findings</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Serum Electrolytes</span></p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (see <a href="#PRECAUTIONS">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Creatinine and Blood Urea Nitrogen</span></p>
<p>As with other ACE inhibitors, minor increases in blood urea nitrogen or serum creatinine, reversible upon discontinuation of therapy, were observed in approximately 1% of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> who were treated with univasc<span class="Sup">®</span>. Increases are more likely to occur in patients receiving concomitant diuretics and in patients with compromised renal function (see <a href="#PreGen">PRECAUTIONS, General</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Italics">Other (causal relationship unknown)</span></p>
<p>Clinically important changes in standard laboratory tests were rarely associated with univasc<span class="Sup">®</span> administration. </p>
<p>Elevations of liver enzymes and uric acid have been reported. In trials, less than 1% of moexipril-treated patients discontinued univasc<span class="Sup">®</span> treatment because of laboratory abnormalities. The incidence of abnormal laboratory values with moexipril was similar to that in the placebo-treated group.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of moexipril have not been reported. In case reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with other ACE inhibitors, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.</p>
<p>No data are available to suggest that physiological maneuvers (e.g., maneuvers to change the pH of the urine) would accelerate elimination of moexipril and its metabolites. The dialyzability of moexipril is not known.</p>
<p>Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of moexipril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, but angiotensin II is essentially unavailable outside of research facilities. Because the hypotensive effect of moexipril is achieved through vasodilation and effective <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, it is reasonable to treat moexipril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> by infusion of normal saline solution. In addition, renal function and serum potassium should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The recommended initial dose of univasc<span class="Sup">®</span> in patients not receiving diuretics is 7.5 mg, one hour prior to meals, once daily. Dosage should be adjusted according to blood pressure response. The antihypertensive effect of univasc<span class="Sup">®</span> may diminish towards the end of the dosing interval. Blood pressure should, therefore, be measured just prior to dosing to determine whether satisfactory blood pressure control is obtained. If control is not adequate, increased dose or divided dosing can be tried. The recommended dose range is 7.5 to 30 mg daily, administered in one or two divided doses one hour before meals. Total daily doses above 60 mg a day have not been studied in hypertensive patients.</p>
<p>In patients who are currently being treated with a diuretic, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occasionally occur following the initial dose of univasc<span class="Sup">®</span>. The diuretic should, if possible, be discontinued for 2 to 3 days before therapy with univasc<span class="Sup">®</span> is begun, to reduce the likelihood of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <a href="#WARNINGS">WARNINGS</a>). If the patient's blood pressure is not controlled with univasc<span class="Sup">®</span> alone, diuretic therapy may then be reinstituted. If diuretic therapy cannot be discontinued, an initial dose of 3.75 mg of univasc<span class="Sup">®</span> should be used with medical supervision until blood pressure has stabilized (see <a href="#WARNINGS">WARNINGS </a> and <a href="#PreDI">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">For patients with a creatinine clearance ≤40 mL/min/1.73 m<span class="Sup">2</span>, an initial dose of 3.75 mg once daily should be given cautiously. Doses may be titrated upward to a maximum daily dose of 15 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">univasc<span class="Sup">®</span> (moexipril hydrochloride) 7.5 mg </span>tablets are pink colored, biconvex, film-coated and scored with engraved code <span class="Bold">707</span> on the unscored side and <span class="Bold">SP</span> above and <span class="Bold">7.5</span> below the score. They are supplied as follows:  </p>
<table width="70%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Bottles of 90 (Unit-of-Use)</td>
<td align="left">NDC 0091-3707-09</td>
</tr>
<tr class="Botrule Last">
<td align="left">Bottles of 100</td>
<td align="left">NDC 0091-3707-01</td>
</tr>
</tbody>
</table>
<p><span class="Bold">univasc<span class="Sup">®</span> (moexipril hydrochloride) 15 mg</span> tablets are salmon colored, biconvex, film-coated, and scored with engraved code <span class="Bold">715</span> on the unscored side and <span class="Bold">SP</span> above and <span class="Bold">15</span> below the score. They are supplied as follows:  </p>
<table width="70%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Bottles of 90 (Unit-of-Use)</td>
<td align="left">NDC 0091-3715-09</td>
</tr>
<tr class="Botrule Last">
<td align="left">Bottles of 100</td>
<td align="left">NDC 0091-3715-01</td>
</tr>
</tbody>
</table>
<p>Store, tightly closed, at controlled room temperature 20° to 25°C (68° to 77°F). Protect from excessive moisture.</p>
<p>If product package is subdivided, dispense in tight containers as described in USP-NF.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>UCB, Inc. <br>Smyrna, GA 30080</p>
<p>Rev. 5E 09/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7.5 mg Tablets Bottle Label</h1>
<p class="First"><span class="Bold">NDC </span>0091-3707-01</p>
<p><span class="Bold">univasc</span><span class="Sup">®</span><span class="Bold"> tablets</span><br>(moexipril HCl)</p>
<p><span class="Bold">7.5 mg</span></p>
<p>Rx only</p>
<p><span class="Bold">100 tablets</span></p>
<div class="Figure"><img alt=" 7.5 mg Tablets Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5&amp;name=univasc-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 mg Tablets Bottle Label</h1>
<p class="First"><span class="Bold">NDC </span>0091-3715-01</p>
<p><span class="Bold">univasc</span><span class="Sup">®</span><span class="Bold"> tablets</span><br>(moexipril HCl)</p>
<p><span class="Bold">15 mg</span></p>
<p>Rx only</p>
<p><span class="Bold">100 tablets</span></p>
<div class="Figure"><img alt="15 mg Tablets Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5&amp;name=univasc-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UNIVASC 		
					</strong><br><span class="contentTableReg">moexipril hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0091-3707</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>moexipril hydrochloride</strong> (moexiprilat) </td>
<td class="formItem">moexipril hydrochloride</td>
<td class="formItem">7.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose (type h)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">707;SP;7;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0091-3707-09</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0091-3707-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020312</td>
<td class="formItem">07/15/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UNIVASC 		
					</strong><br><span class="contentTableReg">moexipril hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0091-3715</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>moexipril hydrochloride</strong> (moexiprilat) </td>
<td class="formItem">moexipril hydrochloride</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose (type h)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (Salmon) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">715;SP;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0091-3715-09</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0091-3715-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020312</td>
<td class="formItem">07/15/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>UCB, Inc.
							(028526403)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ec8857ca-39a4-47ba-868c-dfb38ac04eec</div>
<div>Set id: e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5</div>
<div>Version: 8</div>
<div>Effective Time: 20120731</div>
</div>
</div> <div class="DistributorName">UCB, Inc.</div></p>
</body></html>
